GlassScriptPhysician profile
Meenal Pathak
NPI 1417354903
$1,321.95
in general payments reported to CMS, 2019-2025
6 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $467 · 2024: $654 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $543.41 | 2023-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $374.98 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $132.00 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.25 | 2023 | |
| Axsome Therapeutics, INC. | $76.05 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $70.26 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meenal Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.